Glycoprotein 41 gp41-Pipeline Review, H1 2016

Glycoprotein 41 gp41-Pipeline Review, H1 2016

  • Products Id :- GMDHC0071TDB
  • |
  • Pages: 78
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Glycoprotein 41 (gp41)-Pipeline Review, H1 2016


Global Markets Direct's, 'Glycoprotein 41 (gp41)-Pipeline Review, H1 2016', provides in depth analysis on Glycoprotein 41 (gp41) targeted pipeline therapeutics.

The report provides comprehensive information on the Glycoprotein 41 (gp41), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycoprotein 41 (gp41) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)

The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects

The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Glycoprotein 41 (gp41) Overview 8

Therapeutics Development 9

Glycoprotein 41 (gp41)-Products under Development by Stage of Development 9

Glycoprotein 41 (gp41)-Products under Development by Therapy Area 10

Glycoprotein 41 (gp41)-Products under Development by Indication 11

Glycoprotein 41 (gp41)-Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Glycoprotein 41 (gp41)-Products under Development by Companies 14

Glycoprotein 41 (gp41)-Products under Development by Universities/Institutes 16

Glycoprotein 41 (gp41)-Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Glycoprotein 41 (gp41)-Companies Involved in Therapeutics Development 24

Amunix Operating Inc. 24

BioClonetics Immunotherapeutics, Inc. 25

Frontier Biotechnologies Co., Ltd 26

InnaVirVax SA 27

Laboratorios Del Dr. Esteve S.A. 28

Longevity Biotech, Inc 29

Mymetics Corporation 30

Navigen Pharmaceuticals, Inc. 31

Osel, Inc. 32

Pharis Biotec GmbH 33

Glycoprotein 41 (gp41)-Drug Profiles 34

Biologic for Infectious Disease-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

CLONE-3-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CPT-31-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

DS-007-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Enfuvirtide-XTEN-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

FB-006M-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

HIV vaccine-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

HIV-1 vaccine-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

LBT-5001-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Monoclonal Antibodies to Target GP120 and GP41 for HIV-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

MYMV-101-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

MYMV-201-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Recombinant Peptides for HIV-1-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Sifuvirtide-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Target GP120 and Gp41 for HIV-1 Infections-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

STOP-3S-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Synthetic Peptide to Target gp41 for HIV Infection-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

VAC-02-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

VAC-3S-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

VIR-353-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

VIR-576-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Glycoprotein 41 (gp41)-Dormant Projects 63

Glycoprotein 41 (gp41)-Featured News & Press Releases 64

Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial 64

Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic 64

Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine 66

Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics 67

Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry" 67

Dec 01, 2013: InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used in Combination With Standard Antiretroviral Therapy in Treatment of HIV-Infection 68

Mar 05, 2013: InnaVirVax Presents Results From Phase I/IIa Clinical Study Of VAC-3S At CROI 2013 69

Feb 21, 2013: Mymetics Announces Publication Of Positive Phase I Study Results Of HIV-1 Vaccine In PLOS ONE 69

Nov 30, 2012: InnaVirVax's HIV Vaccine VAC-3S Achieves Primary End Point In Phase I/IIa Study 70

Jun 18, 2012: InnaVirVax Files New European Patent Application For VAC-3S Immunotherapy 71

Mar 05, 2012: InnaVirVax Initiates Phase I/IIa Clinical Trial Of VAC-3S For Treatment Of HIV Infections 71

Oct 13, 2011: InnaVirVax Obtains Authorization From French Drug Agency To Start Phase I/IIa Study Of VAC-3S 72

Sep 19, 2011: HIVACAT identifies candidate to HIV vaccine and initiates animal experimentation 73

Jun 22, 2011: InnaVirVax Announces Positive Preclinical Results Of VAC-3S For Treatment Of HIV Infections 74

May 26, 2011: Mymetics Realizes Successful Phase I Study With New HIV Vaccine MYM-V101 75

Appendix 77

Methodology 77

Coverage 77

Secondary Research 77

Primary Research 77

Expert Panel Validation 77

Contact Us 77

Disclaimer 78

List of Figures

Number of Products under Development for, H1 2016 9

Number of Products under Development by Top 10 Indication, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 13

Assessment by Monotherapy/Combination Products, H1 2016 18

Number of Products by Stage and Mechanism of Actions, H1 2016 19

Number of Products by Routes of Administration, H1 2016 20

Number of Products by Stage and Routes of Administration, H1 2016 20

Number of Products by Molecule Types, H1 2016 22

Number of Products by Stage and Molecule Type, H1 2016 22

List of Tables

Number of Products under Development for, H1 2016 9

Number of Products under Development by Therapy Area, H1 2016 10

Number of Products under Development by Indication, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 13

Number of Products under Development by Companies, H1 2016 14

Products under Development by Companies, H1 2016 15

Number of Products under Investigation by Universities/Institutes, H1 2016 16

Products under Investigation by Universities/Institutes, H1 2016 17

Assessment by Monotherapy/Combination Products, H1 2016 18

Number of Products by Stage and Mechanism of Action, H1 2016 19

Number of Products by Stage and Route of Administration, H1 2016 21

Number of Products by Stage and Molecule Type, H1 2016 23

Pipeline by Amunix Operating Inc., H1 2016 24

Pipeline by BioClonetics Immunotherapeutics, Inc., H1 2016 25

Pipeline by Frontier Biotechnologies Co., Ltd, H1 2016 26

Pipeline by InnaVirVax SA, H1 2016 27

Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016 28

Pipeline by Longevity Biotech, Inc, H1 2016 29

Pipeline by Mymetics Corporation, H1 2016 30

Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 31

Pipeline by Osel, Inc., H1 2016 32

Pipeline by Pharis Biotec GmbH, H1 2016 33

Dormant Projects, H1 2016 63

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Amunix Operating Inc.

BioClonetics Immunotherapeutics, Inc.

Frontier Biotechnologies Co., Ltd

InnaVirVax SA

Laboratorios Del Dr. Esteve S.A.

Longevity Biotech, Inc

Mymetics Corporation

Navigen Pharmaceuticals, Inc.

Osel, Inc.

Pharis Biotec GmbH

Glycoprotein 41 (gp41) Therapeutic Products under Development, Key Players in Glycoprotein 41 (gp41) Therapeutics, Glycoprotein 41 (gp41) Pipeline Overview, Glycoprotein 41 (gp41) Pipeline, Glycoprotein 41 (gp41) Pipeline Assessment

select a license
Single User License
USD 3500 INR 257775
Site License
USD 7000 INR 515550
Corporate User License
USD 10500 INR 773325



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]